106
Participants
Start Date
August 17, 2012
Primary Completion Date
October 3, 2016
Study Completion Date
September 24, 2018
RAD001
Everolimus (C0 trough level of 3-8 ng/mL) in combination with reduced dose tacrolimus and steroids withdrawal at 6 months after transplant
MMF
MMF (Cellcept®): 600mg/m2/dose twice daily (1200 mg/m2/day) in combination with tacrolimus (Prograf) and standard dose steroids
Novartis Investigative Site, Budapest
Novartis Investigative Site, Torino
Novartis Investigative Site, Berlin
Novartis Investigative Site, Stockholm
Novartis Investigative Site, Genova
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Hanover
Novartis Investigative Site, Padua
Novartis Investigative Site, Bologna
Novartis Investigative Site, Essen
Novartis Investigative Site, Münster
Novartis Investigative Site, Lille
Novartis Investigative Site, St Louis
Novartis Investigative Site, Heidelberg
Novartis Investigative Site, Bron
Novartis Investigative Site, Tübingen
Novartis Investigative Site, Paris
Novartis Investigative Site, Paris
Novartis Investigative Site, Los Angeles
Novartis Investigative Site, Ann Arbor
Novartis Investigative Site, Santa Fe
Novartis Investigative Site, Porto Alegre
Novartis Investigative Site, São Paulo
Novartis Investigative Site, Roma
Novartis Investigative Site, Oslo
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Esplugues de Llobregat
Novartis Investigative Site, Antalya
Novartis Investigative Site, London
Novartis Investigative Site, Manchester
Novartis Investigative Site, Nottingham
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY